Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: Case report

Alberto Bongiovanni, Marianna Ricci, Nada Riva, Sebastiano Calpona, Devil Oboldi, Federica Pieri, Davide Cavaliere, Laura Mercatali, Chiara Liverani, Federico La Manna, Alessandro De Vita, Flavia Foca, Erica Gunelli, Dino Amadori, Toni Ibrahim

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors are rare malignancies characterized by c-kit and PDGFR-α mutations targeted by imatinib. Pleural effusion is a very rare side effect of imatinib treatment. A 65-year-old female with metastatic gastrointestinal stromal tumor developed electrolyte imbalance, severe peripheral edema and progressively worsening dyspnea 2 months after starting imatinib. Having excluded cardiovascular and pulmonary disorders, imatinib was discontinued and prednisone 25 mg orally daily was begun. The patient's condition improved substantially over the next 48 h with a progressive decrease in dyspnea and a reduction in pleural effusion and peripheral edema. All side effects had resolved within 1 month. In view of the partial response obtained, the patient re-started imatinib after a 1-week interruption. Prednisone was maintained and there was no further toxicity.

Original languageEnglish
Pages (from-to)2423-2427
Number of pages5
JournalFuture Oncology
Volume10
Issue number15
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Gastrointestinal Stromal Tumors
Pleural Effusion
Prednisone
Dyspnea
Edema
Electrolytes
Imatinib Mesylate
Lung
Mutation
Neoplasms

Keywords

  • gastrointestinal stromal tumor
  • imatinib
  • metastatic gastrointestinal stromal tumor
  • pleural effusion
  • toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib : Case report. / Bongiovanni, Alberto; Ricci, Marianna; Riva, Nada; Calpona, Sebastiano; Oboldi, Devil; Pieri, Federica; Cavaliere, Davide; Mercatali, Laura; Liverani, Chiara; La Manna, Federico; De Vita, Alessandro; Foca, Flavia; Gunelli, Erica; Amadori, Dino; Ibrahim, Toni.

In: Future Oncology, Vol. 10, No. 15, 01.12.2014, p. 2423-2427.

Research output: Contribution to journalArticle

Bongiovanni, Alberto ; Ricci, Marianna ; Riva, Nada ; Calpona, Sebastiano ; Oboldi, Devil ; Pieri, Federica ; Cavaliere, Davide ; Mercatali, Laura ; Liverani, Chiara ; La Manna, Federico ; De Vita, Alessandro ; Foca, Flavia ; Gunelli, Erica ; Amadori, Dino ; Ibrahim, Toni. / Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib : Case report. In: Future Oncology. 2014 ; Vol. 10, No. 15. pp. 2423-2427.
@article{cc37fe030d774cdeac0b5e361ea27b15,
title = "Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: Case report",
abstract = "Gastrointestinal stromal tumors are rare malignancies characterized by c-kit and PDGFR-α mutations targeted by imatinib. Pleural effusion is a very rare side effect of imatinib treatment. A 65-year-old female with metastatic gastrointestinal stromal tumor developed electrolyte imbalance, severe peripheral edema and progressively worsening dyspnea 2 months after starting imatinib. Having excluded cardiovascular and pulmonary disorders, imatinib was discontinued and prednisone 25 mg orally daily was begun. The patient's condition improved substantially over the next 48 h with a progressive decrease in dyspnea and a reduction in pleural effusion and peripheral edema. All side effects had resolved within 1 month. In view of the partial response obtained, the patient re-started imatinib after a 1-week interruption. Prednisone was maintained and there was no further toxicity.",
keywords = "gastrointestinal stromal tumor, imatinib, metastatic gastrointestinal stromal tumor, pleural effusion, toxicity",
author = "Alberto Bongiovanni and Marianna Ricci and Nada Riva and Sebastiano Calpona and Devil Oboldi and Federica Pieri and Davide Cavaliere and Laura Mercatali and Chiara Liverani and {La Manna}, Federico and {De Vita}, Alessandro and Flavia Foca and Erica Gunelli and Dino Amadori and Toni Ibrahim",
year = "2014",
month = "12",
day = "1",
doi = "10.2217/fon.14.159",
language = "English",
volume = "10",
pages = "2423--2427",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "15",

}

TY - JOUR

T1 - Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib

T2 - Case report

AU - Bongiovanni, Alberto

AU - Ricci, Marianna

AU - Riva, Nada

AU - Calpona, Sebastiano

AU - Oboldi, Devil

AU - Pieri, Federica

AU - Cavaliere, Davide

AU - Mercatali, Laura

AU - Liverani, Chiara

AU - La Manna, Federico

AU - De Vita, Alessandro

AU - Foca, Flavia

AU - Gunelli, Erica

AU - Amadori, Dino

AU - Ibrahim, Toni

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Gastrointestinal stromal tumors are rare malignancies characterized by c-kit and PDGFR-α mutations targeted by imatinib. Pleural effusion is a very rare side effect of imatinib treatment. A 65-year-old female with metastatic gastrointestinal stromal tumor developed electrolyte imbalance, severe peripheral edema and progressively worsening dyspnea 2 months after starting imatinib. Having excluded cardiovascular and pulmonary disorders, imatinib was discontinued and prednisone 25 mg orally daily was begun. The patient's condition improved substantially over the next 48 h with a progressive decrease in dyspnea and a reduction in pleural effusion and peripheral edema. All side effects had resolved within 1 month. In view of the partial response obtained, the patient re-started imatinib after a 1-week interruption. Prednisone was maintained and there was no further toxicity.

AB - Gastrointestinal stromal tumors are rare malignancies characterized by c-kit and PDGFR-α mutations targeted by imatinib. Pleural effusion is a very rare side effect of imatinib treatment. A 65-year-old female with metastatic gastrointestinal stromal tumor developed electrolyte imbalance, severe peripheral edema and progressively worsening dyspnea 2 months after starting imatinib. Having excluded cardiovascular and pulmonary disorders, imatinib was discontinued and prednisone 25 mg orally daily was begun. The patient's condition improved substantially over the next 48 h with a progressive decrease in dyspnea and a reduction in pleural effusion and peripheral edema. All side effects had resolved within 1 month. In view of the partial response obtained, the patient re-started imatinib after a 1-week interruption. Prednisone was maintained and there was no further toxicity.

KW - gastrointestinal stromal tumor

KW - imatinib

KW - metastatic gastrointestinal stromal tumor

KW - pleural effusion

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=84920007574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920007574&partnerID=8YFLogxK

U2 - 10.2217/fon.14.159

DO - 10.2217/fon.14.159

M3 - Article

C2 - 25525851

AN - SCOPUS:84920007574

VL - 10

SP - 2423

EP - 2427

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 15

ER -